Get In Touch
Have any questions or comments about the content you see on this page?
Our News
December 11, 2018
Alnylam CEO John Maraganore has been named to the Bloomberg 50 list for 2018. He and Spark Therapeutics CEO Jeff Marrazzo were deemed "the gene medicine revolutionaries" for leading companies that introduced the first groundbreaking genetic treatments derived from the mapping of the human genome.
Click here to read the article on the Bloomberg website.
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site